Stari (603520.SH): Net profit of 12.282,500 yuan in the first quarter increased 28.37% year-on-year
On April 29, Ge Longhui (603520.SH) released its report for the first quarter of 2024, achieving operating income of 642 million yuan, an increase of 13.50%; net profit attributable to shareholders of listed companies of 12.282,500 yuan, an increase of 28.37% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 9.831 million yuan, an increase of 31.85% year on year; basic earnings per share were 0.04 yuan.
Improved Revenues Required Before Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Stock's 28% Jump Looks Justified
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month, although it is still struggling to make up recent
These 4 Measures Indicate That Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Is Using Debt In A Risky Way
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Stary (603520.SH)'s application for fixed addition was approved by the China Securities Regulatory Commission
Stelli (603520.SH) announced that the company received it from the China Securities Regulatory Commission on March 13, 2024...
Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Adds CN¥435m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 77%
It's nice to see the Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) share price up 13% in a week. But only the myopic could ignore the astounding decline over three years. In that time the
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) shares are down a considerable 26% in the last month, which continues a horrid run for the company. For
Stari (603520.SH): Net profit pre-profit of 40 million yuan to 50 million yuan in 2023
Gelonghui, January 30丨Stelli (603520.SH) announced the 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve net profit of 40 million yuan to 50 million yuan for the full year of 2023. Compared with the same period last year, it will turn a loss into a profit. It is expected to achieve net profit of 30 million yuan to 40 million yuan after deducting non-recurring profit and loss attributable to the owners of the parent company in 2023.
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Stock Price Dropped 8.9% Last Week; Retail Investors Would Not Be Happy
Key Insights The considerable ownership by retail investors in Zhejiang Starry PharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy 51% of the bu
[BT Financial Report Instantaneous Analysis] Steali's 2023 Three-Quarter Report: Sales Expansion Drives Profit Growth, and Cash Flow Has Improved Significantly
Zhejiang Sitaili Pharmaceutical Co., Ltd. (stock code: 603520), as an important force in the domestic pharmaceutical industry, focuses on R&D, production and sales of pharmaceutical specialty APIs and formulations. The company has nearly 20 years of industry experience. The product line covers nonionic iodine contrast agent series drugs and levofloxacin series of APIs and intermediates. With rich customer resources and a mature market-oriented business model, Sitaili has taken a place among high-tech pharmaceutical enterprises. From the perspective of assets and liabilities, Stelli's total assets as of the end of the third quarter of 2023 reached 5.7 billion yuan, compared to the end of the previous year
Si Taili (603520.SH): Net profit for the first three quarters was 39.317,500 yuan, up 101.17% year on year
On October 30, Gelonghui (603520.SH) announced its third quarter report. Operating income was 1.63 billion yuan, up 18.43% year on year, net profit was 39.317,500 yuan, up 101.17% year on year, net profit was 39.317,500 yuan, minus non-net profit of 272.16 million yuan, up 520.59% year on year, and basic earnings per share of 0.11 yuan.
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Market Cap Dropped CN¥393m Last Week; Retail Investors Bore the Brunt
Key Insights Zhejiang Starry PharmaceuticalLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 11 shareholders
Si Taili (603520.SH): The application for stock increase was reviewed and approved by the Shanghai Stock Exchange
Si Taili (603520.SH) announced that the company received it on the Shanghai Stock Exchange on October 19, 2023...
Si Taili (603520.SH) announced first-half results and net profit of 35.275,900 yuan, down 44.95% year-on-year
Si Taili (603520.SH) disclosed the 2023 semi-annual report. The company achieved operating income of 10 during the reporting period...
Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Hu Jinsheng, the majority shareholder of Stanley (603520.SH), reduced his shareholding by 1% by a cumulative total
According to the Zhitong Finance App, Si Taili (603520.SH) announced that Hu Jinsheng, a shareholder holding more than 5% of the company's shares, reduced his holdings of the company's shares by a total of 3.4291,000 shares through centralized bidding, accounting for 1% of the company's total share capital.
Did Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Use Debt To Deliver Its ROE Of 7.5%?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval
09:47 PM EST, 02/22/2023 (MT Newswires) -- Zhejiang Starry Pharmaceutical (SHA:603520) obtained approval from China's National Medical Products Administration to market its generic X-ray contrast agen
The Recent CN¥414m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520)
A look at the shareholders of Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) can tell us which group is most powerful. With 39% stake, individual insiders possess the maximum shares in the com
These 4 Measures Indicate That Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Growth Rate Lags the 13% CAGR Delivered to Shareholders
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) shareholders have seen the share price descend 11% over the month. But that doesn't change the fact that the returns over the last five years h
No Data